Comment
doi: 10.1016/j.ccr.2006.10.014.
Restoring cancer's death sentence
Affiliations
- PMID: 17097553
- DOI: 10.1016/j.ccr.2006.10.014
Item in Clipboard
Comment
Restoring cancer's death sentence
Cancer Cell.
2006 Nov.
Free article
Abstract
In this issue of Cancer Cell, two groups present data on the function of an antagonist of BCL-2, ABT-737. Both groups find that expression of MCL-1, an antiapoptotic protein related to BCL-2, is a key determinant of resistance to ABT-737. Lowering MCL-1 levels is an effective adjunct to BCL-2 antagonism, and both groups suggest ways that this might be accomplished practically in a clinical setting. The mechanism by which ABT-737 selectively kills cancer cells is discussed below in the context of these and prior reports of ABT-737's function. Antagonism of BCL-2 is an exciting anticancer strategy that may soon become a clinical reality.
Comment on
-
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.Cancer Cell. 2006 Nov;10(5):375-88. doi: 10.1016/j.ccr.2006.10.006. Cancer Cell. 2006. PMID: 17097560
-
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.Cancer Cell. 2006 Nov;10(5):389-99. doi: 10.1016/j.ccr.2006.08.027. Cancer Cell. 2006. PMID: 17097561 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
